Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J-J Body

Showing results (121-130 of 213) with videos related to

Pageof 22
Sort By:
Cancer Letters|June 19, 2001
Interleukins-6 and -11 expression in primary breast cancer and subsequent development of bone metastasesC Sotiriou, M Lacroix, L Lespagnard, et al.
Clinical Oncology (Royal College of Radiologists (Great Britain))|December 11, 2012
Skeletal-related events and clinical outcomes in patients with bone metastases and normal levels of osteolysis: exploratory analysesA Lipton, R Cook, J Brown, et al.
Journal of Bone and Mineral Research : the Official Journal of the American Society for Bone and Mineral Research|January 1, 1991
Calcitonin secretion in idiopathic renal stone formersM Fuss, T Pepersack, J Corvilain, et al.
BMC Cancer|July 12, 2020
Farnesoid X receptor as marker of osteotropism of breast cancers through its role in the osteomimetism of tumor cellsL Absil, F Journé, D Larsimont, et al.
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer|January 5, 2002
Supportive and palliative care: experience at the Institut Jules BordetI Mancini, D Lossignol, M Obiols, et al.
Histopathology|November 1, 1982
Total parenteral nutrition-induced cholestasis mimicking large bile duct obstructionJ J Body, H Bleiberg, D Bron, et al.
Journal of Bone and Mineral Research : the Official Journal of the American Society for Bone and Mineral Research|May 1, 1996
Administration of the bisphosphonate ibandronate (BM 21.0955) by intravenous bolus injectionM Pecherstorfer, H Ludwig, K Schlosser, et al.
Revue Medicale De Bruxelles|October 28, 2008
[Absolute risk fracture prediction by risk factors validation and survey of osteoporosis in a Brussels cohort followed during 10 years (FRISBEE study)]J J Body, M Moreau, P Bergmann, et al.
Cancer Immunology, Immunotherapy : CII|November 1, 1994
Circulating concentrations of interleukin-6 in cancer patients and their pathogenic role in tumor-induced hypercalcemiaB Vanderschueren, J C Dumon, V Oleffe, et al.
British Journal of Cancer|October 13, 2004
Steroid-free medium discloses oestrogenic effects of the bisphosphonate clodronate on breast cancer cellsF Journe, C Chaboteaux, J-C Dumon, et al.
Pageof 22

Showing results (121-130 of 213) with videos related to

Sort By:
Pageof 22
Cancer Letters|June 19, 2001
Interleukins-6 and -11 expression in primary breast cancer and subsequent development of bone metastasesC Sotiriou, M Lacroix, L Lespagnard, et al.
Clinical Oncology (Royal College of Radiologists (Great Britain))|December 11, 2012
Skeletal-related events and clinical outcomes in patients with bone metastases and normal levels of osteolysis: exploratory analysesA Lipton, R Cook, J Brown, et al.
Journal of Bone and Mineral Research : the Official Journal of the American Society for Bone and Mineral Research|January 1, 1991
Calcitonin secretion in idiopathic renal stone formersM Fuss, T Pepersack, J Corvilain, et al.
BMC Cancer|July 12, 2020
Farnesoid X receptor as marker of osteotropism of breast cancers through its role in the osteomimetism of tumor cellsL Absil, F Journé, D Larsimont, et al.
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer|January 5, 2002
Supportive and palliative care: experience at the Institut Jules BordetI Mancini, D Lossignol, M Obiols, et al.
Histopathology|November 1, 1982
Total parenteral nutrition-induced cholestasis mimicking large bile duct obstructionJ J Body, H Bleiberg, D Bron, et al.
Journal of Bone and Mineral Research : the Official Journal of the American Society for Bone and Mineral Research|May 1, 1996
Administration of the bisphosphonate ibandronate (BM 21.0955) by intravenous bolus injectionM Pecherstorfer, H Ludwig, K Schlosser, et al.
Revue Medicale De Bruxelles|October 28, 2008
[Absolute risk fracture prediction by risk factors validation and survey of osteoporosis in a Brussels cohort followed during 10 years (FRISBEE study)]J J Body, M Moreau, P Bergmann, et al.
Cancer Immunology, Immunotherapy : CII|November 1, 1994
Circulating concentrations of interleukin-6 in cancer patients and their pathogenic role in tumor-induced hypercalcemiaB Vanderschueren, J C Dumon, V Oleffe, et al.
British Journal of Cancer|October 13, 2004
Steroid-free medium discloses oestrogenic effects of the bisphosphonate clodronate on breast cancer cellsF Journe, C Chaboteaux, J-C Dumon, et al.
Pageof 22